Impact of Drug Transporter Gene Variation on Pharmacokinetics and Clinical Outcomes in Chronic Disease Therapy
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 May 2026 | Viewed by 23
Special Issue Editor
2. Regional Institute of Applied Scientific Research IRICA, 13071 Ciudad Real, Spain
Interests: pharmacogenetics/genomics; pharmacokinetics; analytical chemistry; nanomedicines
Special Issue Information
Dear Colleagues,
Chronic diseases (e.g., cardiovascular and metabolic disorders, chronic kidney and liver disease, autoimmune and neurologic conditions) often require lifelong pharmacotherapy, where interindividual variability in exposure, efficacy, and toxicity remains a major challenge. Genetic variation in drug transporters—across ATP-binding cassette (e.g., ABCB1, ABCG2, ABCB11) and solute-carrier families (e.g., SLCO1B1/1B3, SLC22A1/2/8, SLC47A1/2, SLC15A1, SLC10A1)—can alter expression, localization, and function, thereby modifying absorption, distribution, elimination, and, ultimately, clinical response.
This Special Issue invites original research, reviews, and translational/clinical studies that elucidate the impact of transporter gene variants on the pharmacokinetics and clinical outcomes of drugs used in chronic diseases (e.g., statins, antidiabetics, antihypertensives, DOACs, immunosuppressants, antidepressants, antiepileptics). We particularly welcome studies integrating transporter pharmacogenetics with population PK/PBPK modeling, multi-omics, comorbidity and polypharmacy contexts, real-world evidence (biobanks/EHR), and ancestry-aware analyses. Submissions addressing clinical implementation (CPIC/DPWG translation), cost-effectiveness, and decision-support tools for individualized therapy are encouraged.
By consolidating mechanistic clinical evidence, this Special Issue aims to advance precision dosing and improve the safety and effectiveness of long-term treatments in diverse patient populations.
Thus, we are actively soliciting papers on the following topics: (1) Functional and regulatory consequences of transporter variants (common/rare, haplotypes) on PK/PD and exposure–response. (2) Clinical association studies linking genotypes/phenotypes with efficacy, toxicity, and hard outcomes in chronic disease cohorts. (3) Population PK and PBPK modeling incorporating transporter genotype, disease state (e.g., CKD, NAFLD), and drug–drug–gene interactions. (4) Real-world evidence: EHR/biobank analyses, multi-ancestry/sex-stratified effects, and health-equity implications. (5) Co-determinants of variability: Comorbidities, inflammation, organ impairment, polypharmacy, and longitudinal therapy changes. (6) Implementation science: Clinical decision support, guideline translation (CPIC/DPWG), cost–utility analyses, and practice frameworks. (7) Methodological advances: In vitro/in vivo models, transporter phenotyping/probes, imaging, and bioanalytical workflows.
Prof. Dr. Fernando De Andrés
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- drug transporter gene variants
- chronic diseases
- pharmacokinetics
- clinical therapeutic effects
- individualized medication
- ABCB1
- SLC22A family
- SLCO1B1
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
